# A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

> **NCT06643728** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 240 (estimated)

## Conditions studied

- Obesity
- Overweight

## Interventions

- **DRUG:** Bimagrumab
- **DRUG:** Tirzepatide
- **DRUG:** Bimagrumab Placebo
- **DRUG:** Tirzepatide Placebo

## Key facts

- **NCT ID:** NCT06643728
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-21
- **Primary completion:** 2026-04
- **Final completion:** 2027-01
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2025-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06643728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06643728, "A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06643728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*